Article
Identification of cytokine-predominant immunosuppressive class and prognostic risk signatures in glioma
2023-05-10
Abstract excerpt
<h4>Purpose</h4> The advent of immune checkpoint blockade (ICB) therapies this year has changed the way glioblastoma (GBM) is treated. Meanwhile, some patients with strong PD-L1 expression remain immune checkpoint resistant. To better understand the molecular processes that influence the immune environment, there is an urgent need to characterize the immunosuppressive tumor microenvironment and identify biomarker...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d22bc216-cc9a-5ece-babc-9da90e4752de
- DOI
- 10.1101/2023.05.09.539946
